Lachish T, Rudensky B, Slotki I, Zevin S. Enoxaparin dosage adjustment in patients with severe renal failure: antifactor xa concentrations and safety. Pharmacotherapy. 2007;27(10):1347-1352. 95. Yildirim T, Kocak T, Buyukasik Y, et al. Are low-molecular-weight heparins appropriately dosed in patients with CKD stage 3 to 5? Blood Coagul Fibrinolysis. 2012;23(8):700-704. 96. Thorevska N, Amoateng-Adjepong Y, Sabahi R, et al. Anticoagulation in hospitalized patients with renal insufficiency: a comparison of bleeding rates with unfractionated heparin vs enoxaparin. Chest. 2004;125(3):856-863. 97. Barras M. Anti-Xa assays. Aust Prescr. 2013;36(3):98-101. 98. Favaloro EJ, Bonar R, Aboud M, et al; RCPA QAP in Haematology. How useful is the monitoring of (low molecular weight) heparin therapy by anti-Xa assay? A laboratory perspective. Lab Hematol. 2005;11(3):157-162. 99. Favaloro EJ, Bonar R, Sioufi J, et al; Royal College Pathologists of Australasia Quality Assurance Program in Haematology. An international survey of current practice in the laboratory assessment of anticoagulant therapy with heparin. Pathology. 2005;37(3):234-238. 100. Favaloro EJ, Lippi G, Koutts J. Laboratory testing of anticoagulants: the present and the future. Pathology. 2011;43(7):682-692. 101. Egan G, Ensom MH. Measuring anti-factor xa activity to monitor low-molecular-weight heparin in obesity: a critical review. Can J Hosp Pharm. 2015; 68(1):33-47. 102. Deal EN, Hollands JM, Riney JN, Skrupky LP, Smith JR, Reichley RM. Evaluation of therapeutic anticoagulation with enoxaparin and associated anti-Xa monitoring in patients with morbid obesity: a case series. J Thromb Thrombolysis. 2011;32(2):188-194. 103. Lalama JT, Feeney ME, Vandiver JW, Beavers KD, Walter LN, McClintic JR. Assessing an enoxaparin dosing protocol in morbidly obese patients. J Thromb Thrombolysis. 2015;39(4):516-521. 104. Hainer JW, Barrett JS, Assaid CA, et al. Dosing in heavy-weight/obese patients with the LMWH, tinzaparin: a pharmacodynamic study. Thromb Haemost. 2002;87(5):817-823. 105. Smith J, Canton EM. Weight-based administration of dalteparin in obese patients. Am J Health Syst Pharm. 2003;60(7):683-687. 106. 